Výsledky vyhledávání

Akademický článek

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.

Autor: David W Kang, Beate Bittner, Barry J Sugarman, Monica L Zepeda, Marie A Printz

Publikováno v: PLoS ONE, Vol 16, Iss 7, p e0254765 (2021)

BackgroundRecombinant human hyaluronidase PH20 (rHuPH20) facilitates the dispersion and absorption of subcutaneously administered therapeutic agents. This study aimed to characterize the transient, local action of rHuPH20 in the subcutaneous (SC) spa

Externí odkaz: https://doaj.org/article/c07c075fe3a34b4e935d5c8b108458aa

Zobrazit plný text záznamu

Plný text ve formátu HTML

Methods in Medical Ethics: Edited by J Sugarman and D P Sulmasy. Georgetown University Press, 2001, US$ 39.95, pp 314. ISBN 0-87840-873-8

Autor: A Slowther

Publikováno v: Journal of Medical Ethics. 29:6e-6

The editors of this book set out to provide an overview of the various disciplines and methods of inquiry that contribute to medical ethics. The question “what is medical ethics?” is an important and topical one, especially in countries such as t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b33faa999adf9f70ed977be6351f501a
https://doi.org/10.1136/jme.29.4.e6

Zobrazit plný text záznamu

Akademický článek

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

Autor: Marie A. Printz, BA, Samuel S. Dychter, MD, Emanuel P. DeNoia, MD, Rena Harrigan, MPH, Barry J. Sugarman, PhD, Monica Zepeda, PhD, Jennifer Souratha, BSc, David W. Kang, BSc, Daniel C. Maneval, PhD

Publikováno v: Current Therapeutic Research, Vol 93, Iss , Pp 100604- (2020)

ABSTRACT: Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/

Externí odkaz: https://doaj.org/article/9727f714ed4549758640d27883f0f639

Zobrazit plný text záznamu